Daniel H. Mathalon

Feb 9, 2024 | biologicalpsychiatryjournal.com | Daniel H. Mathalon

Over 2-3 years of follow-up, only 15-20 % of individuals at clinical high risk for psychosis (CHR-P) convert to psychosis, 20-30% of CHR-P non-converters achieve remission. These variable outcomes and low conversion/remission rates pose challenges for drug development and personalized treatments. Accordingly, biomarkers that predict clinical outcomes are needed.

Dec 7, 2023 | biologicalpsychiatryjournal.com | Noah Lewis |Peter Kochunov |Daniel H. Mathalon

AbstractSchizophrenia research reveals sex differences in incidence, symptoms, genetic risk factors, and brain function. However, a knowledge gap remains regarding sex-specific schizophrenia alterations in brain function. Schizophrenia is considered a dysconnectivity syndrome, but the dynamic integration and segregation of brain networks are poorly understood. Recent advances in resting-state fMRI allow us to study spatial dynamics, the phenomenon of brain networks spatially evolving over time.